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GENETIC DISORDERS – DEVELOPMENT
A functional immature model of chronic partial
ureteral obstruction1
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A functional immature model of chronic partial ureteral ob-
struction.
Background. The most common nonlethal congenital
anomaly of the urinary tract is ureteral obstruction without
dysplasia. Although rarely progressive, the morbidity associ-
ated with metabolic and surgical management is considerable.
Our study was designed to measure local and systemic patho-
physiologic mechanisms in an immature model of chronic par-
tial unilateral ureteral obstruction (UUO) after completion of
glomerulogenesis.
Methods. A partial UUO was created by the method of “psoas
wrap” in young male weanling rats. Control animals were sham
operated. Three groups were divided as follows: sham (N =
15), UUO (N = 18), and UUO + angiotensin-converting en-
zyme (ACE) (N = 16) inhibitor, enalapril. Renal glomerular
and tubular functions were determined by creatinine and uric
acid clearances. Diuresis was assessed by urine volume, osmo-
lality, and fractional solute excretions from samples above and
below the obstruction. Proteinuria was determined by the urine
protein/creatinine ratio (Up/c).
Results. Proteinuria was attenuated in UUO + ACE-treated
animals. The hyperuricemia of the immature UUO animals was
avoided by an increase in the clearance of uric acid in the UUO
+ ACE-treated group. Fractional solute excretions suggested a
diversion of diuresis to the contralateral unobstructed kidney.
Conclusion. Angiotensin blockade during chronic UUO in
young rats affords protection by attenuating proteinuria, pro-
moting uricosuria, and diverting solute diuresis. These data sug-
gest a complex interaction of local and systemic mechanisms
unique to the maturing kidney.
1See Editorial by Chevalier, p. 1517.
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Congenital obstructive uropathy in infants and chil-
dren accounts for a significant number of pediatric
patients with progressive renal disease associated with
dysplasia and abnormal glomerulogenesis [1–4]. The
most common lesion, occurring in over 1% of pregnancies
and over 12% of nonlethal congenital fetal malforma-
tions, is obstruction without dysplasia [2, 5]. The diagno-
sis has become more prevalent during recent years with
the universal availability of intrauterine ultrasound [6].
A fervent debate has evolved regarding the appropriate
surveillance and timing of surgical intervention in infants
and children with ureteropelvic (UPJ) or ureterovesicle
junction (UVJ) obstruction [7, 8]. No reliable clinical
markers have been developed to gauge the severity of
lesions, although it is apparent that the immature kidney
is more vulnerable to insult [5, 9]. One certainty is that
adult models cannot be extrapolated to children, nor can
the newborn rodent models of complete obstruction with
renal dysplasia be compared to the more benign UPJ [4,
5]. The current study offers a simple functional model of
chronic partial unilateral ureteral obstruction (UUO) in
immature animals to examine local and systemic effects
that are unique to the developing kidney. A potential
nonsurgical therapeutic intervention is explored.
METHODS
Study design
All experiments were performed on healthy male
weanling Wistar rats weighing 74 ± 16 g ± SD at the
time of surgery. All animals were housed under standard
conditions of heat and humidity on a 12-hour light cycle
with unlimited access to regular rat chow and water. Sixty
rats were divided equally into three study groups. The
control group was sham operated. Forty rats underwent
partial left ureteral obstruction by a simplified “psoas
wrap” described below. Twenty were allocated to therapy
with the angiotensin-converting enzyme (ACE) inhibitor,
enalapril, which was administered in the drinking water in
a concentration of 200 mg/L. This provided an estimated
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dose of 0.2 mg/kg/day at the estimated ad libitum water
intake of 10 to 15 mL/100 g body weight/day. The groups
were designated as sham, UUO, and UUO + ACE. After
21 days, two 24-hour urine samples were collected in se-
quence with the rats in metabolic cages. Then the animals
were sacrificed by exsanguination and urine was obtained
from the bladder and dilated renal pelvis when possible.
All surgery and procedures were performed under deep
general ketamine-xylazine anesthesia (40/5 mg/kg). The
study was approved by the Animal Care and Use Com-
mittee of the University of Miami School of Medicine in
compliance with the regulations established for the hu-
mane treatment of laboratory animals.
Surgical preparation of UUO
After induction of deep general anesthesia under
aseptic techniques and with ampicillin prophylaxis
(100 mg/kg), a midline longitudinal abdominal incision
was made that permitted access to the left kidney, ureter,
and psoas muscle. Partial UUO was accomplished by en-
veloping the lower left ureter in the psoas muscle with
a single suture of 4-0 silk transfixing the muscle later-
ally and medially creating a muscular tunnel through
which the ureteral segment was gently compressed. Un-
like larger animal models [10, 11], no surgical groove was
made in the psoas. In sham operated rats, the ureter was
exposed but not obstructed.
Kidney measurements
After 21 days, the rats were sacrificed. The dilatation of
the left collecting system proximal to the psoas wrap was
measured. The left kidney was removed from all animals.
Weights and measurements were obtained, including
length, width, and pelvic width at the time of sacrifice. The
renal parenchymal weight was obtained after removal of
the kidney and decompression of the open renal pelvis
ex vivo with blotting of urine by an absorbent pad. The
contralateral unobstructed right kidney was removed and
measured as described above for the UUO and UUO +
ACE groups.
Histopathology
At sacrifice, the kidneys were excised and fixed in 10%
buffered formalin. They were bivalved and submitted for
histologic processing. Coronal sections were cut at 5 l and
stained with hematoxylin and eosin (H&E) and periodic
acid-Schiff (PAS) and trichrome stain for histologic ex-
amination. The kidneys were examined by a pathologist
without previous knowledge of the treatment received by
the animals. The following histopathologic features were
analyzed and recorded: cortical and medullary thickness
in microns, blunting of medullary pyramids, presence or
absence of cortical and/or medullary cysts, cortical and/or
medullary fibrosis, renal pelvis dilatation, and presence or
absence of glomerulogenesis [11, 12].
Renal functional studies
Renal glomerular and tubular functions were deter-
mined by creatinine and uric acid clearances. Clear-
ances were calculated as the product of the urine volume
(V) and solute concentration (UX) divided by the
plasma concentration (Px) over time (t) expressed as
milliliters/minute/100 grams body weight (mL/min/100
g body weight) for creatinine clearance and mL/hour/
100 g body weight for uric acid clearance. The equation
was as follows:
Cx = UXV/Pxt
Diuresis was assessed by urine volume, osmolality, and
fractional solute excretions. Fractional solute excretions
(FeX) of samples obtained above the obstruction from
the renal pelvis and below the obstruction from the blad-
der were calculated as the fraction of the solute (x)
cleared relative to the clearance of creatinine expressed
as a percentage (%) as follows:
FeX (%) = UXPcreatinine/UcreatininePx ∗ 100
An advantage of this calculation is that it cancels the
volume integer eliminating the error imposed by urine
collections.
Proteinuria was determined by the 24-hour urine ex-
cretion expressed as milligrams/total volume (UprV).
Whereas comparisons above and below the obstruction
were by the ratio of urine protein:creatinine (Up/c) in
milligrams protein/milligrams creatinine [13].
Chemical analyses
Urine and plasma chemistries were performed on a
Kodak multichannel autoanalyzer against rat standards.
Statistical analysis
Univariate comparisons between and within groups
were made with the use of one-way analysis of variance
(ANOVA). Differences between groups were deter-
mined by Tukey’s multiple comparisons tests. Com-
parisons between ipsilateral and contralateral kidney
measurements within the same experimental group were
made by the paired t test. Results were considered signif-
icant when P values were <0.05. Data are expressed as
means ± standard deviation (SD), while graphics show
means ± standard error of the mean (SE). All graphs
and statistical analyses were determined using the Graph
Pad statistical software referenced by Motulsky [14].
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Sham UUO UUO+ACE
Fig. 1. Whole renal sections. Representative whole renal sections of
left kidneys from each experimental group demonstrating the distinct
differences between the treated and untreated unilateral ureteral ob-
struction (UUO). See Table 1 for average measurements from each
group and statistical comparisons.
RESULTS
Physical and anatomic measurements
The growth of animals in each group was comparable
for both length and body weight during the 21-day pe-
riod. They progressed from immature weanling animals
(average weight 74 ± 15 g) to mature young adults with
final weight averaging 227 ± 23 g (interval gain 170 ±
20 g).
Whole renal sections of representative left kidneys
from each group demonstrate the differences noted with
whole kidney measurements (Fig. 1) (Table 1). Significant
renal pelvic dilatation was noted in both UUO groups.
The mean renal pelvic diameter was significantly greater
in the untreated UUO compared to the UUO + ACE
group (8 ± 4 mm versus 4 ± 3 mm ± S.D; P < 0.003). The
length and width of the sham kidneys were significantly
less than that of either UUO group (P < 001). How-
ever, the left kidney parenchymal weights of the sham and
UUO + ACE were closely similar (0.95 g versus 0.94 g)
and significantly less than that of the untreated UUO
(1.14 g) (Table 1). When ipsilateral obstructed kidneys
were compared to their contralateral pairs, length and
width was significantly less in the unobstructed kidneys.
Moreover, the mean parenchymal weight of the ipsilat-
eral obstructed UUO + ACE-treated kidney was sig-
nificantly less than that of its contralateral partner and
similar to the sham control (P = 0.04).
Histopathology
Histologic comparisons including the full perspective
extending from the deepest cortical layer to the renal
capsule are shown in Figure 2. None of the examined
kidneys had evidence of active glomerulogenesis. Corti-
cal and medullary thickness were decreased in the kid-
neys with UUO as compared to sham-treated animals
and contralateral kidneys. The medullary pyramids were
either absent or blunted in the kidneys with UUO, but
were normal in the sham-operated and contralateral kid-
neys. The UUO group had cortical cysts and the other
groups did not have any cysts. However, the histologic
A B C
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Fig. 2. Composite photomicrograph from sham, unilateral ureteral ob-
struction (UUO), and UUO +angiotensin-converting enzyme (ACE).
(A to C) Cortex. (D to F) Renal medulla (trichrome stain). (A) and
(D) (sham) demonstrate normal cortex and medulla. There is a sharp
contrast with (B) and (E) in the kidney with UUO. Observe increased
interstitial fibrosis in cortex and medulla as well as decreased medullary
thickness. Notice that the open space at the lower portion of photomi-
crograph (F) demonstrates renal pelvis. In other words, the entire renal
medulla from this kidney is shown. There are also cortical and medullary
cysts in (B) and (E), respectively. (C) and (F) are from an enalapril-
treated animal whose kidney was subjected to UUO. There is mild
medullary fibrosis and absence of cortical and medullary cysts. Inter-
nal scale 100 l.
features in the UUO + ACE group were not as striking
as in the UUO group.
Renal function and proteinuria
Although creatinine clearance as an indication of
glomerular filtration rate (GFR) showed a tendency to
be less in the UUO-untreated group, the difference did
not reach significance (Table 2). Proteinuria as measured
by the Up/c ratio was markedly attenuated in the UUO +
ACE group. Figure 3 is a composite graph showing the to-
tal protein excretions for the experimental UUO groups
on the left with the comparisons between the urines ob-
tained from above the obstruction and from the bladder
in both the UUO and UUO + ACE groups. The signifi-
cant local attenuation of proteinuria from the obstructed
unit treated with ACE is apparent as well as the “dilu-
tional” effect of the proteinuria in the bladder urines.
Diuresis and solute excretion
Daily urine volume was similar in all groups (Table 2).
Figure 4 is a composite graph showing the effect of
total and fractional solute excretions relative to the
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Table 1. Comparable renal measurements
Unilateral ureteral obstruction (UUO) kidney Contralateral kidney
Weight Length Width Renal pelvis Weight Length Width
Group (N) g mm mm mm g mm mm
Sham (15) 0.95 ± 0.1 20 ± 2a 12 ± 1a 0.95 ± 0.1 20 ± 2 12 ± 1
UUO (18) 1.12 ± 0.4a 26 ± 5 19 ± 6 8 ± 4 1.2 ± 0.3 20 ± 2 13 ± 2
UUO + ACE (16) 0.94 ± 0.1 25 ± 4 19 ± 5 4 ± 3b 1.1 ± 0.1 20 ± 1 12 ± 1
ACE is angiotensin-converting enzyme.
aIndicates significant difference from other groups P < 0.01; bSignificantly different from UUO P < 0.001.
Table 2. Renal functional studies
Sham UUO UUO + ACE ANOVA
Variable (N) (15) (18) (16) P value
Urine volume mL/day 17 ± 4 17 ± 7 19 ± 2 NS
Creatinine clearance 0.70 ± 0.5 0.32 ± 0.3 0.68 ± 0.4 NS
mL/min/100 g
body weight
Uric acid clearance 0.91 ± 0.6 0.54 ± 0.3 2.01 ± 1.5a 0.03
mL/hour/100 g
body weight
Proteinuria (UprV) 3.8 ± 1.3 23.6 ± 38a 2.7 ± 2.3 0.04
mg/day
Abbreviations are: UUO, unilateral ureteral obstruction; ACE, angiotensin-
converting enzyme; ANOVA, analysis of variance.
aIndicates significant difference from other groups.
contralateral unobstructed units in both the treated and
untreated UUO groups. Total urinary solute excretions as
urine osmolality and fractional excretions of sodium and
potassium are shown on the left. Comparisons between
the urines obtained from above and below the obstruction
are shown on the right. Significant differences were noted
in the local effects of UUO + ACE treated animals. Urine
osmolality as an indicator of net solute excretion was sig-
nificantly less in the renal pelvis of the UUO + ACE
group but was similar in the UUO renal pelvis and blad-
der urines of both UUO and UUO + ACE. The fractional
excretions of sodium (UUO 2.5% ± 2.0 versus UUO +
ACE 0.8% ± 0.4; P = 0.02) and potassium (UUO 79% ±
32 versus UUO + ACE 53% ± 23; P < 0.05) from daily
urines were significantly less in the UUO + ACE group
(Fig. 4).
Uric acid
Hyperuricemia was a prominent abnormality in the un-
treated UUO group while serum uric acid was normal in
the UUO + ACE group. Figure 5 is a composite graph
that depicts the alterations in plasma uric acid and in-
creased uric acid excretion mediated by treatment with
ACE during chronic UUO. These changes occurred while
renal function (creatinine clearance) and daily diuresis
(V) were similar in each group.
DISCUSSION
This study emphasizes the unique vulnerability of the
immature animal to systemic manifestations of UUO as
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Fig. 3. Proteinuria. This composite shows the total protein excretions
by 24-hour urines for the unilateral ureteral obstruction (UUO) groups
on the left with the comparisons between the urines obtained from
above the obstruction and from the bladder in both the UUO and UUO
+ angiotensin-converting enzyme (ACE) groups. The “local” attenua-
tion of proteinuria to the obstructed unit treated with ACE is apparent
as well as the “dilutional” effect of the proteinuria into the bladder
urines. Statistical differences are by the standard t test on the left and
analysis of variance (ANOVA) on the right. ∗Significant difference from
UUO group; ∗∗Significant difference from UUO pelvis and bladder
values.
well as the potential protection offered by angiotensin
blockade [15]. The protection appears to be three
pronged and is associated with a measurable decrease in
proteinuria, alterations in solute excretion and diuresis,
as well as uric acid excretion. Although multifaceted, the
primary sites of action may be localized to the glomeru-
lus (proteinuria), distal tubule and collecting duct (solute
diuresis), and the proximal tubule (uric acid excretion).
The latter two sites strongly suggest systemic responses
to the chronic unilateral obstruction, which is consistent
with our previous clinical observations in infants with
both unilateral and bilateral hydronephrosis [16]. A de-
tailed assessment of possible mechanisms is warranted
in consideration of future therapeutic interventions and
research into the pathophysiology of obstruction of the
urinary tract in children when renal dysplasia is not a
factor.
Clinical and laboratory observations have consistently
shown that proteinuria is an adverse event associated
with progressive renal injury that is particularly ominous
in the setting of reflux nephropathy and obstruction [17,
18]. Numerous studies in adults have shown that medical
management with angiotensin blockade decreases pro-
teinuria and preserves renal function [18, 19]. The most
extensively studied pathology is diabetic nephropathy
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Fig. 4. Solute excretion. This composite
shows the effect of total daily urinary so-
lute excretions as urine osmolality and frac-
tional excretions of sodium and potassium on
the left. Comparisons between the urines ob-
tained from above and below the obstruc-
tion are shown on the right. The renal pelvic
urines are above the obstruction and repre-
sent the maximum local effect of the obstruc-
tion and the treatment. The bladder urines
are dilutional from the partial obstruction and
primarily represent the contralateral unob-
structed renal unit if the ratio of bladder to
pelvis values exceeds 1. ∗Significant difference
from unilateral ureteral obstruction (UUO)
group(s); ∗∗Significant difference from UUO
bladder values.
Table 3. Differential solute and protein excretions distributed above
the obstruction (renal pelvis) and mixed within the bladder
UUO UUO + ACE
Pelvis Bladder Pelvis Bladder P
Variable(N) (8) (8) (10) (12) value
Urinary sodium NA 1.6 ± 0.7 NA 1.5 ± 0.5 NS
volume mmol/L/
day
Urinary potassium 3.4 ± 1.6 3.5 ± 0.9 NS
volume mmol/L/
day
Urinary osmolarity 872 ± 600 911 ± 340 407 ± 159a 820 ± 169 0.01
mOsm/L
Fractional excretion 4.5 ± 4.2 2.5 ± 2 1.9 ± 2.7 0.8 ± 0.3 NS
of sodium %
Fractional excretion 30 ± 19 79 ± 32b 49 ± 38 53 ± 23 0.02
of potassium %
Fractional excretion 3.2 ± 1.6 4.4 ± 3.4 11.6 ± 4.6c 7.2 ± 6.5 0.004
of uric acid %
Proteinuria (Up/c) 23 ± 43 6.8 ± 7.9 1.2 ± 2.2d 0.6 ± 0.4c 0.007
Abbreviations are: UUO, unilateral ureteral obstruction; ACE, angiotensin-
converting enzyme.
aSignificantly different from all other values; bSignificantly different from UUO
pelvis; cSignifcantly different from both UUO pelvis and bladder; dSignificantly
different from UUO bladder.
and the remnant kidney model with decreased renal mass
[20]. Treatment with angiotensin blockade leads to a de-
crease in individual glomerular hyperfiltration with con-
trol of proteinuria as one measurable benefit, although
other less well-defined mechanisms are known to exist
[21]. The pathologic correlate of UUO as a cause of pro-
teinuria is well documented and our model substantiates
that this is a direct effect of local tissue injury [18–21]. The
remarkable response to the ACE treatment in alleviating
proteinuria is gratifying in that it confirms the validity of
the model as well as the adequacy of dosing and delivery
of the medication in the drinking water.
The next therapeutic benefit offered by the ACE inhi-
bition was the measurable decrease in hydronephrosis of
the obstructed kidney. Since the daily urine volume for
each group of animals was similar, there appeared to be
a diversion of solute diuresis to the contralateral kidney
in both the treated and untreated groups (i.e., compen-
satory hyperfiltration). The protective mechanism of the
ACE inhibition appears to be linked to a decrease in so-
lute excretion with a reduction of urine flow behind the
obstruction in ACE-treated animals. This leads to the as-
sumption that direct alterations in solute traffic mediate
urine volume in this setting, which is consistent with the-
oretical models [22].
In adults with UUO, the contralateral unobstructed
kidney is capable of compensating for the damaged re-
nal unit without consequence to its own integrity [18].
Release of obstruction is followed by diuresis and recov-
ery of function in the ipsilateral and contralateral kidney
[17, 18]. In contrast, the immature unobstructed kidney
appears to be more vulnerable to hyperfiltration [23]. An-
imal [1–3] and human studies [23] indicate a potential for
progression to end-stage renal disease (ESRD) in infants
with congenital obstructive uropathy whether associated
with unilateral or bilateral disease.
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Fig. 5. Uric acid alterations independent of renal function and diure-
sis. This composite graph depicts the alterations in plasma uric acid and
increased uric acid excretion mediated by treatment with angiotensin-
converting enzyme (ACE) during chronic unilateral ureteral obstruc-
tion (UUO) while global renal function (creatinine clearance) and daily
diuresis (V) are similar in each group. ∗Significant difference from other
groups.
During chronic UUO, the immature animal may be
more sensitive to the pathologic mechanisms of an ad-
versarial renin angiotensin aldosterone system (RAAS)
for numerous reasons, including an imbalance in the re-
ceptors for angiotensin II. The differential action of these
receptors is not fully understood, although some evidence
suggests an important function of the angiotensin II type
2 (AT2) receptors in the modulation of interstitial fibrosis
and the up regulation of nitric oxide in the interstitium
[24, 25]. Future investigation is necessary to unravel the
developmental role of the different angtiotensin II recep-
tors in congenital obstructive uropathy.
The final focus of interest in the present study is the
mechanism of hyperuricemia in the setting of UUO in
the immature model. Uric acid, as a systemic indicator
of inflammation and as a local perpetrator of endothelial
injury, has received renewed attention in clinical and lab-
oratory investigation [26]. The immaturity of the model
deserves consideration since adult rodents (and lower
mammals other than humans and the Great Apes) do not
develop hyperuricemia with renal disease due to the per-
sistence of the enzyme uricase [27, 28]. Our study docu-
ments the induction of hyperuricemia in this young model
and demonstrates a remedial effect of RAAS block-
ade. The renal handling of uric acid is complex and is
linked to proximal tubular sodium and bicarbonate re-
absorption. Proximal tubular sodium and bicarbonate
reabsorption in the adult is biphasic, although primar-
ily dependent on angiotensin II type 1 (AT1) receptors
[24]. Moreover, interaction between the systemic RAAS
and the corticotropin-insulin-somatotropin axes include
a link between insulin and proximal sodium and urate re-
absorption [29, 30]. Numerous laboratory studies suggest
a fertile avenue for research into these hormonal-genetic
mediators of health and disease as they apply to the im-
mature UUO model [31, 32].
The development of a functional in vivo model of con-
genital UUO seems essential for studying the pathophys-
iology and potential medical interventions. An important
methodologic concept in this and future functional mod-
els is the estimation of bladder urine dilution from the
unobstructed contralateral kidney. The application of
a mathematical model to define the “differential renal
functional compensation” could provide important in-
sights into future therapies [22]. Such a model could be
exploited to study both animal and human subjects with
minimally invasive techniques.
Although our findings demonstrate therapeutic bene-
fits of ACE inhibition in congenital UUO, caution is war-
ranted since such treatment of infants carries important
potential toxicity. Normal glomerulogenesis is dependent
on the function of the RAAS in utero with its interactive
cascade [31–33]. Antagonism of the RAAS during preg-
nancy and in preterm and newborn infants has resulted
in severe consequences, including renal dysgenesis and
acute renal failure [34–36].
CONCLUSION
Angiotensin blockade in the model of UUO in young
rodents appears to alleviate heavy proteinuria, decrease
hydronephrosis, and promote uricosuria in apparent re-
nal protection. This model offers an opportunity to study
the complex pathophysiology of chronic UUO so that
clinical markers of progressive injury can be developed
and therapeutic interventions may be planned.
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